News & Events

The patient, treated at the Casey Eye Institute in Portland, Oregon, belongs to a group of 18 people affected with Leber congenital amaurosis. These patients will participate in the BRILLIANCE study, the first clinical trial to determine the safety and efficacy of a therapy based on the CRISPR-Cas9 gene editing technique (AGN-151587, EDIT-101). It is the first example of an...

First gene therapy application of Luxturna in the UK

26/02/20 - Leber Congenital Amaurosis, Retinal Dystrophy, Therapy, Gene Therapy,

This February Moorfields Eye Hospital in London and Radcliffe Hospital in Oxford have started treating patients affected by Leber congenital amaurosis (LCA) with the Luxturna gene therapy. LCA is a childhood-onset severe retinal dystrophy, which causes irreversible blindness for which, until now, no treatment was available. Luxturna (voretigene neparvovec) is also the first gene therapy approved for the treatment of an...

DBGen’s genetic diagnosis of hereditary eye diseases tops the 1,000 patients figure

21/01/20 - DBGen, Genetic Diagnosis,

We are glad to announce that early this year DBGen Ocular Genomics has achieved more than 1,000 genetic diagnoses of hereditary visual disorders. The genetic diagnosis of hereditary eye diseases is not without a high degree of complexity. Over 270 genes associated with inherited retinal dystrophies (IRDs) and more than 500 genes associated with visual disorders with a Mendelian inheritance...

DBGen second anniversary and summary of the year

30/12/19 - DBGen, Genetic Diagnosis,

DBGen Ocular Genomics is a spin-off of the University of Barcelona specialized in the genetic diagnosis of hereditary eye disorders. It was founded in January 2018 by Roser Gonzàlez-Duarte and Gemma Marfany, both senior scientists focussed in human molecular genetics, particularly in the genetic basis of ocular disorders. DBGen Ocular Genomics aims to provide an accurate genetic diagnosis to guide...

Novel dual-vector delivery system for Stargardt disease gene therapy

02/12/19 - Macular degeneration, Stargardt, Gene Therapy,

The American biotechnology company Applied Genetic Technologies Corporation (AGTC), specialized in the development of gene therapies for rare diseases, has just announced Stargardt disease as its new preclinical gene therapy program in ophthalmology. Stargardt disease characterized by a progressive loss of central vision affects one in 8,000-10,000 individuals and is the most common form of inherited macular degeneration. The first...

Researchers devise a novel, high-precision, gene-editing tool to fix genetic diseases

18/11/19 - Gene editing, Gene Therapy,

In recent years, a powerful gene-editing technology called CRISPR-Cas9 has revolutionized biology turning the process of genome modification into an easy and inexpensive process. This revolutionary technique makes use of molecular tools that allow precise identification of DNA fragments –for example a gene– and either introduce modifications, delete a genomic fragment, or even insert a new DNA fragment or a...

< 1 2 3 4 … 8 >